Please login to the form below
Loxo
This page shows the latest Loxo news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly’s Verzenio label expanded by FDA for early breast cancer patients
Jacob Van Naarden, chief executive officer of Loxo@Lilly, said: "This expanded approval will allow us to bring Verzenio to many more women and men with HR-positive, HER2-negative, high
Latest news
-
Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours
Since its initial accelerated approval, Retevmo has shifted the treatment paradigm for patients with RET-altered cancers," said David Hyman, chief medical officer, Loxo@Lilly.
-
Lilly and Foghorn sign oncology deal
Loxo Oncology, an R&D group within Eli Lilly &Co, is betting that highly selective BRAHMA inhibitors are the key to addressing BRG1 mutated cancers. ... difficult chemistry challenge,” said Jacob Van Naarden, Loxo CEO and president of Lilly Oncology.
-
FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
Loxo Oncology at Lilly and president, Lilly Oncology.
-
Lilly restructures in preparation for Alzheimer’s drug launch
Jacob (Jake) Van Naarden, currently chief executive officer of Loxo Oncology, will bring together and lead Loxo and Lilly Oncology, and join Lilly's executive committee.
-
Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
Eli Lilly – through its Loxo Oncology R&D development group – has signed an exclusive collaboration agreement with Kumquat Biosciences to develop novel small molecules that stimulate tumour-specific responses. ... chief executive officer of Loxo
More from news
Approximately 8 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
This is the first US product approval for Loxo Oncology and its marketing partner Bayer, becoming the second company to get FDA backing for a drug that treats cancer based on ... NTRK fusions are rare – Loxo estimates that there are around 2, 500 to 3,
-
Cancer immunotherapy: What's on the horizon?
also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.
-
Deal Watch table for July 2013
485. Array BioPharma / Loxo Oncology. Multi-year licence and collaboration. Drug candidate (preclinical) discovery of small molecule drugs for oncology targets.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
